Biodegradable Implant with [Poly(PDL-co-DO)] Co-Polymers
LNG Biodegradable Implant, Yale BDI
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Long-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Yale University, FHI 360
Details
- API: Levonorgestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Endometrial Changes
- Cervical Mucus Changes
- Ovulation Inhibition
- Inactive Materials: [poly(PDL-co-DO)]
- Regimen: 1 Insertion/18 Months
- MPT: Not Potential MPT
- Promising Attributes: BDIs are anticipated to provide an intermediate duration of contraceptive efficacy, in between current injectables and current implants, while having the advantage of bioabsorbing in situ with no need for removal.
Product Status
Active/Recent Pre-Clinical Development
History
The Saltzman Research Group at Yale University has led development of a [poly(PDL-co-DO)]-based biodegradable implant since at least 2010, with support from USAID through FHI 360. The research group was granted a US patent on the design and manufacturing process for the BDI in 2023, and public presentations in 2024 indicate active development of an LNG-releasing implant. Per the presentations, Yale may pursue development of the method as a treatment for endometriosis, rather than a primary contraceptive indication.